In the summer of 2018, the FDA learned that some generic ARB medications, including valsartan, irbesartan, losartan and others contained nitrosamine impurities— including N-Nitrosodimethylamine (NDMA) ...
Elemental impurity risk management can help biomanufacturers to maintain regulatory alignment and ensure patient safety.